How Stool Screening for CRE Helps
Stool screening for carbapenem-resistant Enterobacterales (CRE) identifies asymptomatic carriers who serve as hidden reservoirs for transmission, enabling early isolation and contact precautions that reduce CRE infections by 53% and deaths by 68% per 1000 patients screened 1.
Primary Benefits: Breaking the Chain of Transmission
The fundamental value of stool/rectal screening lies in detecting colonized patients before they spread CRE to others. Many patients carry CRE in their intestinal tract without symptoms, yet they actively shed these organisms and contaminate their environment 2. Without screening, these silent carriers remain unrecognized and continue standard care without isolation precautions, facilitating patient-to-patient transmission through healthcare worker hands, shared equipment, and environmental contamination.
Quantified Clinical Impact
The most recent comprehensive guideline demonstrates that active CRE screening prevents:
- 13 fewer CRE infections per 1000 patients (RR = 0.47,95% CI 0.29-0.77)
- 12 fewer deaths per 1000 patients (RR = 0.32,95% CI 0.16-0.64) 1
These mortality benefits are substantial—screening directly saves lives by preventing progression from colonization to invasive infection.
Who Should Be Screened
Prioritize screening for these high-risk populations 1:
- Patients with prior CRE colonization/infection history - highest risk group
- Patients sharing wards with known CRE carriers - exposure-based screening
- Patients expected for ICU admission (including neonatal ICU) - pre-emptive identification
- Patients with hematologic malignancy before chemotherapy or transplantation - immunocompromised hosts
When a hospital-associated CRE case is identified, conduct single-round surveillance of all patients with epidemiologic links (same unit, same healthcare personnel) 2.
Optimal Screening Methodology
Use rectal swabs, perirectal swabs, or stool specimens 2. These gastrointestinal samples provide higher yield than other body sites like nares or skin because CRE primarily colonizes the intestinal tract. Recent data shows direct stool Xpert Carba-R assay achieves 97.2% sensitivity and 99.1% specificity 3, though gene-level concordance with culture varies (particularly false-positive blaIMP-1 detections).
What Happens After Positive Screening
Immediate Actions
Once screening identifies a CRE carrier:
- Place patient on contact precautions immediately 2
- Single-room isolation preferred; provide separate toilet 1
- Cohorting isolation acceptable when single rooms unavailable, but only for patients colonized with the same CRE species 1
- Dedicate nursing staff to CRE patients—they should not care for other patients 1
Preventing Progression to Infection
Among colonized patients, 37.2% develop subsequent CRE infections 4, with mortality reaching 65.2% in those who progress from colonization to infection versus only 13% in those who remain colonized 5. The most common infection sites are lower respiratory tract, bloodstream, and urinary tract 4.
Key risk factor for progression: Having more than three comorbidities (OR = 0.118,95% CI 0.017-0.812) 4. Patients with this profile require intensified monitoring.
Surveillance Strategy Based on Local Epidemiology
Low-Prevalence Settings (Most U.S. Hospitals)
- Do NOT perform routine admission screening for all patients 2
- Conduct targeted screening only when cases are identified
- Perform point prevalence surveys in high-risk units (ICUs, units with prior cases, units with heavy antimicrobial use) 2
- Repeat weekly surveillance until no new cases identified 2
High-Endemic Settings
In regions where CRE is routinely recovered (e.g., New York City, certain international settings with 17.6% carrier rates 6):
- Consider risk-based pre-admission screening 6
- Implement intensified Tier 2 infection control strategies if rates not decreasing 2
- Point prevalence surveys may be less useful; continuous surveillance more appropriate 2
Common Pitfalls to Avoid
Screening without action is futile: The Puerto Rico outbreak demonstrated that screening alone doesn't work—compliance with hand hygiene was only 48% and gown/glove use only 62%, hindering outbreak control despite identifying carriers 2. Screening must be coupled with rigorous infection control adherence.
Don't stop screening prematurely: Continue periodic surveillance (e.g., weekly) until no new cases emerge 2. Only when repeated surveys fail to identify colonized patients can you consider halting active surveillance and switching to periodic point prevalence surveys 2.
Resource limitations require prioritization: When isolation rooms are scarce, prioritize single-room isolation for patients with fecal/urinary incontinence, invasive devices, or continuous wound secretions 1. These patients pose highest transmission risk.
Molecular Epidemiology Insights
Recent surveillance reveals ST11-KL64 KPC-producing Klebsiella pneumoniae as the dominant clone in many settings 7, 4, with clonal spread within ICU wards. This homology between colonizing and infecting strains confirms that colonized patients serve as the source for their own subsequent infections and for transmission to others 4.
Real-World Implementation Success
A Chinese pediatric study implementing active CRE screening with >80% isolation compliance reduced nosocomial CRE infection rates from 1.96% to 0.63% in neonatal ICU and from 0.57% to 0.30% in general neonatal wards 1. Similarly, a Shanghai ICU study showed active screening with infection prevention interventions reduced CRE infection rates from 11.4% to 7.1% 7.